| Bisphosphonates |
| Risedronate (Actonel) | 5 mg orally once a day | Prevention or treatment of postmenopausal osteoporosis |
| 35 mg orally once a week | Treatment of glucocorticoid-induced osteoporosis |
| 5 mg orally once a day |
| Alendronate (Fosamax) | 5 mg orally once a day | Prevention of postmenopausal osteoporosis |
| 35 mg orally once a week | |
| 10 mg orally once a day | Treatment of postmenopausal osteoporosis |
| 70 mg orally once a week | |
| 5 mg orally once a day (10 mg orally once a day in postmenopausal women not receiving estrogen) | Treatment of glucocorticoid-induced osteoporosis |
| 10 mg orally once a day | Treatment of osteoporosis in men |
| 70 mg orally once a week | |
| Hormones | | |
| Conjugated equine estrogen | 0.625 mg orally once a day | Prevention of postmenopausal osteoporosis |
| Various estrogen preparations | Dosage depends on agent. | Prevention of postmenopausal osteoporosis |
| Recombinant human parathyroid hormone | | |
| Teriparatide (Forteo) | 20 mcg SC once a day | Treatment of postmenopausal osteoporosis |
| Treatment to increase bone mass in men with osteoporosis who are at high risk for fracture |
| Selective estrogen receptor modulator | | |
| Raloxifene (Evista) | 60 mg orally once a day | Prevention or treatment of postmenopausal osteoporosis |
| Salmon calcitonin (Miacalcin) | 200 IU intranasally once a day (alternating nostrils daily) | Treatment of postmenopausal osteoporosis |
| | 100 units SC or IM every other day | |